Department of Anaesthesia, Royal Victoria Hospital, Belfast BT12 6BA, UK
*Corresponding author. Email: peter.farling{at}dnet.co.uk
Accepted for publication: January 22, 2004
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Br J Anaesth 2004; 92: 8935
Keywords: anaesthetics opioid, remifentanil; anaesthetic techniques, epidural; metabolism, endocrine, carcinoid; surgery, small bowel resection
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Case report |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Twenty-four hour urine collection revealed normal catecholamines but raised concentrations of 5-hydroxyindoleacetic acid of 236 µmol 24 h1 (normal range 1047 µmol 24 h1). The concentration of liver enzymes was slightly elevated. Computerized tomography and an octreotide-somatostatin receptor study indicated liver metastases. A liver biopsy, guided by ultrasound, was consistent with carcinoid tumour and a bone scan identified involvement of the thoracic cage and sacrum. No focal lesion was identified by a small bowel series but capsule endoscopy,3 a new investigation that provides direct endoscopic visualization of the small bowel with computerized imaging, indicated a small polyp in the ileocaecal region. The plasma concentration of the gastrointestinal hormone neurokinin A was significantly elevated at 150 ng litre1 (normal range 020 ng litre1). This finding was in keeping with a diagnosis of a mid-gut carcinoid tumour.
Subcutaneous octreotide 200 µg three times per day relieved the symptoms of diarrhoea and flushing so the longer acting somatostatin analogue, lanreotide, 120 mg monthly by i.m. injection, was prescribed for ongoing control of symptoms. The patient was scheduled for laparotomy, liver biopsy and probable small bowel resection.
Pre-anaesthetic history and examination confirmed the previous findings. Anaesthetic history included an uneventful appendicectomy 30 yr previously and mastoidectomy 20 yr previously. Haemoglobin, urea, electrolytes and chest radiograph were normal. The ECG showed sinus bradycardia with first-degree AV block but no evidence of valvular heart disease.
Premedication included subcutaneous octreotide 100 µg and oral temazepam 20 mg. I.V. access was established and an epidural catheter was placed at the T12L1 interspace with 8 cm of catheter left in the epidural space. A 3 ml test dose of bupivacaine 0.25% was injected to exclude intrathecal placement, but no further epidural bupivacaine was injected until towards the end of the procedure. An arterial line was inserted and vasopressors (phenylephrine and ephedrine), vasodilators (including sodium nitroprusside) and octreotide were readily available. An infusion of remifentanil was commenced at 0.2 µg kg1 min1. Anaesthesia was induced with propofol 150 mg and neuromuscular blockade was provided by vecuronium 10 mg with incremental doses of 2 mg throughout surgery. Anaesthesia was maintained by an infusion of remifentanil 0.2 µg kg1 min1 and sevoflurane 1% in an air/oxygen mixture. A central venous line was placed in the right internal jugular vein and a urinary catheter and nasogastric tube inserted. A test dose of morphine 2 mg was given before surgery started without any haemodynamic disturbance or urticaria. After 35 min, the remifentanil infusion was reduced from 0.2 µg kg1 min1 to 0.15 µg kg1 min1. No bolus doses of remifentanil were required.
Additional drugs included ondansetron 8 mg, cefuroxime 1.5 g and metronidazole 500 mg. Octreotide 100 µg diluted into 10 ml with sodium chloride 0.9% was prepared for management of any intraoperative carcinoid crisis, but was not required. During the operation, there was an episode of flushing when the tumour was handled, but no evidence of bronchospasm.
The entire procedure lasted 4 h; arterial pressure, heart rate and central venous pressure remained virtually unchanged throughout the procedure. Laparotomy confirmed multiple large metastases throughout the liver, one of which was biopsied. A small, mobile, intraluminal tumour was resected from the terminal ileum, followed by an end-to-end anastomosis. Blood loss was minimal and intraoperative fluids consisted of Ringer lactate 1 litre and saline 0.9% 1 litre.
Towards the end of the operation, epidural anaesthesia was established with a titrated injection of bupivacaine 0.25% 10 ml, and continued after surgery with a continuous infusion, via an Abbott pain management provider pump, of bupivacaine 0.1% with fentanyl 5 µg ml1 at a rate of 810 ml h1. Octreotide, antibiotics and enoxaparin were continued. Postoperative recovery was uneventful. Histological examination of the resected specimen confirmed the diagnosis of carcinoid tumour.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Preoperative treatment with the somatostatin analogue octreotide has been shown to improve the perioperative course of these patients.1 6 Premedication with subcutaneous octreotide 100 µg suppresses serotonin and kinin activity during surgery.4 Additional factors in the operative setting that trigger the release of carcinoid mediators include the response to intubation, inadequate analgesia, hypotension, the use of drugs that release histamine, intraoperative tumour handling and hypertension, which causes the release of bradykinin. In a recent series, 43% of patients received vasopressors, either phenylephrine or ephedrine, and 38% of patients required intraoperative octreotide. The median dose of octreotide was 350 µg.1
Unlike morphine and pethidine, remifentanil has very little potential for histamine release. While little has been written on this topic, remifentanil has been suggested to reduce the likelihood of histamine release in patients with mastocytosis.7 Severe hypotension after administration of morphine has been reported in such a patient.8 Remifentanil infusion has the advantages of good suppression of the intubation response, adequate analgesia, rapid titratability and the ability to control any intraoperative hypertension. These attributes are useful in the management of a patient with carcinoid syndrome. A potential disadvantage is the occurrence of hypotension, especially at higher infusion rates. At an infusion rate of 0.150.2 µg kg1 min1, the haemodynamic variables were virtually unchanged in this patient. Other narcotics that have been used in the management of carcinoid syndrome include sufentanil and fentanyl.9 10
There is a risk that epidural anaesthesia could cause hypotension, triggering mediator release and a carcinoid crisis.11 However, the successful use of epidural anaesthesia for transurethral resection of the prostate in a patient with carcinoid syndrome has been reported,12 although it is worth noting that the tumour was not being manipulated in this case.
In our patient, epidural analgesia was adequate and did not produce any adverse haemodynamic consequences during the postoperative period of 72 h, after which the catheter was removed. The use of epidural analgesia is only advised in carcinoid patients who have been adequately treated before surgery with octreotide and provided that local anaesthetic is administered in a graded manner with careful haemodynamic monitoring. A diluted concentration of bupivacaine 0.1% is advised in the postoperative period.
A test dose of i.v. morphine was administered after induction without any haemodynamic consequences. This was given to find whether patient controlled analgesia (PCA) with morphine was an option in the postoperative period, if epidural analgesia failed or caused significant hypotension. Those wishing to completely avoid the potentially harmful effects of morphine may choose PCA with fentanyl as a safer option.6
In summary, the combination of intraoperative remifentanil infusion and postoperative epidural analgesia is a helpful addition to the recommended technique for the anaesthetic management of a patient with carcinoid syndrome.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 Breslin DS, Farling PA, Mirakhur RK. The use of remifentanil in the anaesthetic management of patients undergoing adrenalectomy: A report of three cases. Anaesthesia 2003; 58: 35862[ISI][Medline]
3 Fritscher-Ravens A, Swain CP. The wireless capsule: new light in the darkness. Dig Dis 2002; 20: 12733
4 Vaughan DJ, Brunner MD. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 1997; 35: 12942[ISI][Medline]
5 Wilde IM, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996; 52: 77394[ISI][Medline]
6 Veall GR, Peacock JE, Bax ND, Reilly CS. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72: 33541[ISI][Medline]
7 Auvray L, Letrourneau B, Freysz M. Mastocytosis: general anaesthesia with remifentanil and sevoflurane. Ann Fr Anesth Reanim 2001; 20: 6358[ISI][Medline]
8 Vaughan ST, Jones GN. Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 1998; 53: 8049[CrossRef][ISI][Medline]
9 Mehta AC, Rafanan AL, Bulkley R, Walsh M, DeBoer GE. Coronary spasm and cardiac arrest from carcinoid crisis during laser bronchoscopy. Chest 1999; 115: 598600
10 Connolly HM, Schaff HV, Mullany CJ, et al. Surgical management of left-sided carcinoid heart disease. Circulation 2001; 104: 13640
11 Mason RA, Steane PA. Carcinoid syndrome: its relevance to the anaesthetist. Anaesthesia 1976; 31: 22842[ISI][Medline]
12 Monteith K, Roaseg OP. Epidural anaesthesia for transurethral resection of prostate in a patient with carcinoid syndrome. Can J Anaesth 1990; 37: 34952[Abstract]
|